Stockscreener 앱 받기
4.50
1.75%
-0.08
전일 마감가:
$4.58
열려 있는:
$4.44
하루 거래량:
698.26K
Relative Volume:
0.53
시가총액:
$292.87M
수익:
$69.23M
순이익/손실:
$-33.10M
주가수익비율:
-3.8136
EPS:
-1.18
순현금흐름:
$-39.26M
1주 성능:
+1.12%
1개월 성능:
+27.48%
6개월 성능:
+298.23%
1년 성능:
+18.11%
1일 변동 폭
$4.355
$4.55
1주일 범위
$4.18
$4.6402
52주 변동 폭
$0.52
$5.92
Neuronetics Inc Stock (STIM) Company Profile
명칭
Neuronetics Inc
전화
877-600-7555
주소
3222 PHOENIXVILLE PIKE, MALVERN, PA
STIM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
STIM
Neuronetics Inc
|
4.50 | 292.87M | 69.23M | -33.10M | -39.26M | -1.18 |
|
ABT
Abbott Laboratories
|
132.60 | 224.65B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
104.24 | 151.13B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
381.36 | 139.34B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
83.45 | 107.01B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
75.11 | 44.25B | 5.54B | 4.18B | 259.90M | 7.00 |
Neuronetics Inc Stock (STIM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-13 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-10-13 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2021-10-13 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-01-22 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2020-02-06 | 개시 | BTIG Research | Buy |
| 2018-07-24 | 개시 | Canaccord Genuity | Buy |
모두보기
Neuronetics Inc 주식(STIM)의 최신 뉴스
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | STIM Stock News - GuruFocus
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Neuronetics Expands Team with 4,500 Share RSU Package for Three New Strategic Hires - Stock Titan
Transcranial Magnetic Stimulator Market Generated - openPR.com
Neuronetics, Inc.'s (NASDAQ:STIM) 30% Jump Shows Its Popularity With Investors - simplywall.st
Neuronetics Announced as a Winner by 2022 Merit Awards for HealthCare in the Patient Care Category - IT Business Net
Geode Capital Management LLC Buys 8,466 Shares of Neuronetics, Inc. (NASDAQ:STIM) - Defense World
Taking the lead: Neuronetics Inc (STIM) - Sete News
Insider’s View: Deciphering Neuronetics Inc (STIM)’s Financial Health Through Ratios - DWinneX
Neuronetics Inc (STIM) stock on the rise: An overview - uspostnews.com
Why Neuronetics, Inc. (STIM) is Surging in 2025 - Insider Monkey
Transneural Therapeutics Appoints CNS Drug Development Expert, Mark A. Demitrack, MD, as Chief Research and Development Officer - The Malaysian Reserve
Neuronetics, Inc.'s (NASDAQ:STIM) market cap surged US$39m last week, individual investors who have a lot riding on the company were rewarded - simplywall.st
Neuronetics to Announce Q1 2025 Results and Host Live Conference Call on May 6 - MSN
Was there any good news for Neuronetics Inc (STIM) stock in the last session? - uspostnews.com
Neuronetics to Report First Quarter 2025 Financial and Operating Results and Host Conference Call | STIM Stock News - GuruFocus
Neuronetics to Report First Quarter 2025 Financial and Operating Results and Host Conference Call - The Manila Times
Medical Tech Leader Neuronetics Sets Q1 2025 Earnings Release: Key Details for Neurohealth Investors - Stock Titan
Neuronetics, Inc. (NASDAQ:STIM) Short Interest Update - Defense World
Neuronetics Reports 2024 Financial Results and Strategic Advances - MSN
Transcranial Magnetic Stimulator Market to Witness Remarkable - openPR.com
Neuronetics Announces Expanded Coverage for NeuroStar TMS to Treat Adolescent Depression - MSN
Even though Neuronetics (NASDAQ:STIM) has lost US$30m market cap in last 7 days, shareholders are still up 130% over 5 years - simplywall.st
Evernorth Health Services, a Cigna Company, Expands NeuroStar® TMS Coverage for Adolescents Struggling with Depression - The Manila Times
Major Insurance Breakthrough: NeuroStar's Teen Depression Treatment Now Covered for 15 Million Lives - Stock Titan
Neuronetics Revises Financial Results for Q4 and Full Year 2024 - MSN
Neuronetics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Neuronetics: Explosive Growth Poised To Soar On FDA Breakthroughs (NASDAQ:STIM) - Seeking Alpha
Neuronetics Reports Updated Fourth Quarter and Full Year 2024 Financial and Operating Results - The Manila Times
Neuronetics Some Non-Cash Revisions Made To Financial Statements Related To Co's Acquisition Of Greenbrook Tms & Shares Outstanding In Q4 - Marketscreener.com
Neuronetics Updates Financial Results: Q4 Losses Deepen After Greenbrook Deal Review - Stock Titan
Transcranial Magnetic Stimulator Market Is Booming So Rapidly - openPR.com
This Penny Stock Is Up 170% in 2025 and Analysts Think It Can Rally Further From Here - The Globe and Mail
FDA Clears NeuroStar's TMS Therapy for Adolescents with Major Depressive Disorder - MSN
While private equity firms own 38% of Neuronetics, Inc. (NASDAQ:STIM), retail investors are its largest shareholders with 43% ownership - Yahoo
Wall Street Analysts Think Neuronetics (STIM) Could Surge 34.98%: Read This Before Placing a Bet - Yahoo Finance
Neuronetics Inc (STIM) Q4 2024 Earnings Report Preview: What To Look For - GuruFocus.com
Transcranial Magnetic Stimulator Market Positioned - openPR
Neuronetics’ SWOT analysis: merger synergies boost growth prospects for stock - Investing.com India
Earnings call transcript: Neuronetics Q4 2024 sees revenue growth, stock rises - Investing.com Australia
Neuronetics, Inc. to Host Earnings Call - ACCESS Newswire
William Blair Increases Earnings Estimates for Neuronetics - Defense World
Neuronetics Inc (STIM) Reports 8% Revenue Growth in Q3 2023 - GuruFocus.com
Neuronetics CFO Stephen Furlong sells $8,364 in stock - Investing.com India
Neuronetics (NASDAQ:STIM) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says - Defense World
(STIM) Technical Data - news.stocktradersdaily.com
Neuronetics executive sells shares worth $1,688 By Investing.com - Investing.com Canada
Neuronetics executive sells shares worth $1,688 - Investing.com India
Neuronetics CFO Stephen Furlong sells $8,364 in stock By Investing.com - Investing.com UK
Neuronetics Inc (STIM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
11.62%
0.20%
자본화:
|
볼륨(24시간):